Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00811902 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 405
- Enrollment target
NCT00811902: Completed Phase 2 study, sponsored by Sanofi.
NCT00811902 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 405 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (205% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00811902, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 405 participants
- Enrollment target
Study Summary
The primary objective is to assess the activity of nerispirdine in improving the ability to walk, in patients with multiple sclerosis (MS). Secondary objectives: * To assess other measures of walking ability, tiredness, and lower limb muscular strength, spasticity, clinical assessment by subject and clinical assessment of change by the Study Investigator * To assess the safety and tolerance of nerispirdine * To evaluate the pharmacokinetics (PK) parameters of nerispirdine
Interventions
- DRUG placebo
- DRUG Nerispirdine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
What the finished NCT00811902 record still lists
NCT00811902 is an interventional study that assigns participants to a tested intervention. The registered 405 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (205% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00811902 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00811902 about?
NCT00811902 is a clinical study titled "Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis". The primary objective is to assess the activity of nerispirdine in improving the ability to walk, in patients with multiple sclerosis (MS). Secondary objectives: * To assess other measures of walking ability, tiredness, and lower limb muscular strength, spasticity, clinical assessment by subject a...
What is the current status of trial NCT00811902?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 405 participants. The study started on 2008-12. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00811902?
The interventions under investigation include: placebo (DRUG), Nerispirdine (DRUG).
Who is sponsoring clinical trial NCT00811902?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00811902's enrollment target sits among peer trials
405 95th of 2000 higher than 1,906 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05576350 · 405 participants · NA
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
- NCT07066657 · 405 participants · Phase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- NCT06223360 · 406 participants · Phase 2
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
- NCT06411769 · 406 participants · NA
Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia